Curaleaf beats prelim Q4 revenue estimates, discontinues hemp business, exits Missouri

Curaleaf Holdings

20/01/2026 13:38

Overview

Cannabis products provider's preliminary Q4 revenue rises, beating analyst expectations

Company to discontinue hemp business and exit Missouri due to regulatory changes

Adjusted gross profit margin for Q4 expected to be approximately 48.5%

Outlook

Company anticipates full-year 2025 adjusted gross margin of 50%

Curaleaf plans to release full financial results by early March 2026

Result Drivers

REGULATORY CHANGES - Co decided to discontinue hemp business due to new federal regulations limiting THC content

MARKET EXIT - Co to cease operations in Missouri due to sub-scale presence

REVENUE GROWTH - Q4 revenue grew 4% sequentially, exceeding previous guidance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$330 mln
$326.50 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Curaleaf Holdings Inc is C$5.00, about 38.5% above its January 19 closing price of C$3.61

Press Release: ID:nPn6QNCBha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)